

## Triumeq/Triumeq PD (abacavir/dolutegravir/lamivudine) – Expanded indication

- On June 15, 2023, the <u>FDA approved</u> ViiV Healthcare's <u>Triumeq and Triumeq PD</u>
   (<u>abacavir/dolutegravir/lamivudine</u>), for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
  - Triumeq and Triumeq PD were previously approved for this indication in adults and in pediatric patients weighing at least 10 kg.
  - Triumeq and Triumeq PD alone are not recommended in patients with resistanceassociated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in Triumeq and Triumeq PD is insufficient in these subpopulations.
- Triumeq and Triumeq PD carry a boxed warning for hypersensitive reactions and exacerbations of hepatitis B.
- The recommended dose of Triumeq PD for the treatment of HIV-1 infection in pediatric patients 6
  kg to < 10 kg is 3 tablets once daily (180 mg abacavir, 15 mg dolutegravir, and 90 mg lamivudine
  once daily). Triumeq PD is administered as a tablet for oral suspension.</li>
  - Triumeq tablets are not recommended for patients 6 kg to < 10 kg.</li>
  - Refer to the Triumeq and Triumeq PD drug label for dosing for other age groups.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.